UK equities opened the week lower on Monday as rising geopolitical tensions in the Middle East pushed oil prices above $100 per barrel, weighing on investor sentiment across global markets. European equities also declined while the pound traded near $1.33 against the US dollar.
As of 08:36 GMT, the FTSE 100 had fallen about 1.6%. The British pound weakened by roughly 0.8% against the dollar to $1.3306. Elsewhere in Europe, Germany’s DAX dropped around 2.3%, while France’s CAC 40 declined about 2.6%.
Energy markets were a key driver of the negative sentiment. Brent crude futures climbed to approximately $104.31 by 08:41 GMT as investors reacted to the escalating conflict in the Middle East, raising concerns over potential disruptions to global oil supply.
Experts weigh in
Analysts at Jefferies noted that recent attention in financial markets has centred on European and UK interest rate expectations. Current market pricing suggests more than 1.5 rate hikes from the European Central Bank and fewer than one interest rate cut from the Bank of England in 2026.
According to the firm, recent moves in short-term interest rate markets appear largely driven by position adjustments rather than a shift in inflation expectations.
Jefferies maintains its base-case view that the ECB will keep policy unchanged this year. Even with oil prices climbing, analysts believe central banks are unlikely to react unless crude remains above $100 for a prolonged period and begins generating broader inflationary pressures.
If oil prices fall back below $80 within roughly three months, the firm does not expect any meaningful impact on ECB policy decisions.
UK round-up
M&C Saatchi (LSE:SAA) said Monday that chief executive Zaid Al-Qassab will step down from his role and leave the board on 31 March 2026 by mutual agreement with the company.
Current non-executive chair Dame Heather Rabbatts will take on the role of interim executive chair while the company conducts a formal search for a permanent CEO. During the transition period, she will work with senior leadership and an operating board formed from the company’s executive team to continue executing its growth strategy.
Separately, GSK plc (LSE:GSK) announced a licensing agreement with Italian pharmaceutical group Alfasigma S.p.A., granting it worldwide exclusive rights to develop, manufacture and commercialise linerixibat.
Linerixibat is an investigational ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. The therapy is currently under regulatory review in multiple regions including the United States, European Union, United Kingdom, China and Canada.
The drug has received Orphan Drug Designation in the US, EU and Japan, and has also been granted priority review in China for the treatment of cholestatic pruritus associated with primary biliary cholangitis.









